Skip to main content Skip to main navigation menu Skip to site footer

Gynecological malignancy with obstructive uropathy patient profile in Cipto Mangunkusumo Hospital: Our 2-year experience



Abstract

Introduction: Gynecological malignancies are one of the most common causes of death from cancer in women. Hydronephrosis or obstructive uropathy is the most common finding in patients with gynecological malignancy. This study aimed to describe the profile of obstructive uropathy patients causes of gynecology malignancies treated in our center from 2019 to 2021.

Method: From January 2019 to January 2021, obstructive uropathy patients with gynecological malignancies who underwent DJ stent or nephrostomy insertion procedures at Cipto Mangunkusumo Hospital were included in this prospective study. Patients with a history of urinary diversion or other diseases that may cause urinary tract obstruction were excluded.

Result: One hundred and twenty-one patients with gynecological malignancies with obstructive uropathy were included. Cervical carcinoma was the most common cause, followed by ovarian carcinoma and endometrial carcinoma. The percentages of bilateral, right-, and left-sided stenting were 72%, 18%, and 10%, respectively. Most of them were grade 3 or grade 4 hydronephrosis. Percutaneous nephrostomy was mainly used for 69,4%, and only 17% of patients experienced a polyuria episode.

Conclusion: Most cases of obstructive uropathy were caused by cervical malignancies, with bilateral obstruction due to cervical cancer occurring in most cases. Nephrostomy is the method of choice for urinary drainage in our center.

Keywords: gynecological malignancy obstructive uropathy nephrostomy stent hydronephrosis

References

  1. Parkin DM, Muir CS, Whelan SL, Gao YT, Ferlay J, Powell J.Cancer Incidence in Five Continents, Vol. VI. Lyon: IARC Scientific Publications No. 120, 1992.
  2. Ortiz V, Kiehl R. Obstrução do trato urinário causas e condutas. In: Schor N, Srougi M. Nefrologia urologia clínica. São Paulo: Sarvier, 1998. p.198-204.
  3. Sasmol S, Ghosh B, Banerjee PM, Dilip P, Pal K. Factors predicting renal recoverability after percutaneous nephrostomy in obstructive uropathy. 2016;4:3497–502.
  4. Pergialiotis V, Bellos I, Thomakos N, Haidopoulos D, Perrea DN, Kontzoglou K, et al. Survival outcomes of patients with cervical cancer and accompanying hydronephrosis: A systematic review of the literature. Oncol Rev. 2019;13(1):23–9.
  5. Mishra K, Desai A, Patel S, Mankad M, Dave K. Role of Percutaneous Nephrostomy in Advanced Cervival Carcinoma with Obstructive Uropathy: A Case Series. Indian J Palliat Care. 2009;15: 37-40.
  6. Dave PS, Patel BM, Patel H, Mankad MH. Obtructive uropathy in gynecologic malignancy and value of percutaneous nephrostomy. GCSMC J Med Sci. 2015; 4: 114-9
  7. Patel K, Foster NR, Kumar A, Grudem M, Longenbach S, Bakkum-Gamez J, et al. Hydronephrosis in patients with cervical cancer: an assessment of morbidity and survival. Support Care Cancer. 2015;23(5):1303–9.
  8. Hsu L, Li H, Pucheril D, et al. Use of percutaneous nephrostomy and ureteral stenting in management of ureteral obstruction. World J Nephrol. 2016;5(2):172-181. doi:10.5527/wjn.v5.i2.172
  9. Hyppolite JC, Daniels ID, Friedman EA. Obtructive uropathy in gynecologic malignancy. Detrimental effect of intraureteral stent placement and value of percutaneous nephrostomy. ASAIO J. 1995; 41: M318-23.
  10. Gonzalez CM. Pathophysiology, diagnosis, and treatment of the postobstructive diuresis. In: McVary KT, editor. Management of benign prostatic hypertrophy. New York, NY: Humana Press; 2004. pp. 35–45
  11. Esparaz AM, Pearl JA, Herts BR, LeBlanc J, Kapoor B. Iatrogenic urinary tract injuries: etiology, diagnosis, and management. Semin Intervent Radiol. 2015;32(2):195-208. doi:10.1055/s-0035-1549378
  12. Suprasert P, Euathrongchit J, Suriyachai P, Srisomboon J. Hydronephrosis after radical hysterectomy: a prospective study. Asian Pac J Cancer Prev. 2009 Jul-Sep;10(3):375-8. PMID: 19640176.
  13. Hsu L, Li H, Pucheril D, et al. Use of percutaneous nephrostomy and ureteral stenting in management of ureteral obstruction. World J Nephrol. 2016;5(2):172-181
  14. Kurata S, Tobu S, Udo K, Noguchi M. Outcomes of ureteral stent placement for hydronephrosis in patients with gynecological malignancies. Curr Urol. 2016;10:126-31
  15. Elsheemy MS, Shouman AM, Shoukry AI, et al. Ureteric stents vs percutaneous nephrostomy for initial urinary drainage in children with obstructive anuria and acute renal failure due to ureteric calculi: A prospective, randomised study. BJU Int. 2015;115(3):473-479. doi:10.1111/bju.12768
  16. Mittal V, Biswas M, Lal S. Percutaneous nephrostomy or double J stenting, which is better modality for obstructive uropathy-a descriptive study. Int J Res Med Sci. 2016;4(8):3486-3491. doi:10.18203/2320-6012.ijrms20162317
  17. Azadi ZK, Norhayati MN, Abdullah MS. Percutaneous nephrostomy versus retrograde ureteral stenting for acute upper obstructive uropathy: a systematic review and meta-analysis. Sci Rep. 2021;11:6613.
  18. Shoshany O, Erlich T, Golan S, et al. Ureteric stent versus percutaneous nephrostomy for acute ureteral obstruction - clinical outcome and quality of life: a bi-center prospective study. BMC Urol. 2019;19(1):79

How to Cite

Affan, M. I. F., Harrina Erlianti Rahardjo, & Fina Widia. (2022). Gynecological malignancy with obstructive uropathy patient profile in Cipto Mangunkusumo Hospital: Our 2-year experience. Bali Medical Journal, 10(3). https://doi.org/10.15562/bmj.v10i3.2925
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver
Download Citation
Endnote/Zotero/Mendeley (RIS) BibTeX

HTML
0

Total
2

Share

Search Panel

Muhammad Isa Fuad Affan
Google Scholar
Pubmed
BMJ Journal

Harrina Erlianti Rahardjo
Google Scholar
Pubmed
BMJ Journal

Fina Widia
Google Scholar
Pubmed
BMJ Journal